All News

India has confirmed 2 Nipah infections in West Bengal as surveillance tracks 196 contacts with no spread, with the World Health Organization outlining symptoms, transmission, and response measures.

Emerging ultraprecision therapies target CALR mutations in myelofibrosis, promising more effective treatments and improved patient outcomes for pharmacists.

Changes to the federal childhood vaccine schedule have created confusion and variation in practice, placing added responsibility on clinicians and pharmacists to educate patients and ensure evidence-based care.

During American Heart Month, Sarah Nelson, PharmD, highlights how pharmacists can leverage frequent patient interactions, risk assessment tools, and medication optimization strategies to reduce cardiovascular risk.

Legislation targeting the practices of pharmacy benefit managers (PBMs) was passed by Congress and signed by the president, with the goal of greater transparency and increased pharmacy access.

Pharmacists enhance multiple sclerosis care through collaborative practice agreements, improving patient outcomes and bridging gaps in treatment and education.

MFN drug pricing ties Medicare payments to the lowest prices abroad, promising lower costs but sparking legal, access, and innovation concerns.

Study results suggest young participants who survived cancer have difficulty in areas such as memory, attention, and ability to process information compared with those who did not have cancer.

Experts discuss how atebimetinib and adjusted chemotherapy schedules enhance tolerability and treatment duration for patients with pancreatic cancer.

Phase 1 data show oral NSD2 inhibitor KTX-1001 delivers durable disease control in high-risk myeloma, with manageable thrombocytopenia and combo plans.

Experts discuss the role of pharmacists in CAR T-cell and gene therapy at the 2026 ASTCT Tandem Meeting in Salt Lake City.

As biomedical research output continues to grow, so does the demand for professionals who can accurately interpret data and communicate it responsibly to diverse audiences.

COVID-19 significantly impacts diagnosis rates for depression, asthma, and osteoporosis, revealing health care inequities and the need for improved monitoring.

Craig Beavers is joined by the investigators of the POLY-HF trial to reinforce the critical role of pharmacist counseling and education in treating patients with heart failure.

A pharmacist-physician model significantly reduces wait times for atrial fibrillation care, enhancing patient access and treatment effectiveness in underserved areas.

Replacing animal products—particularly processed meats—with plant-based foods, including some processed options, can lower cardiometabolic risk and offer pharmacists practical counseling opportunities alongside medication therapy.

Pharmacists learn how protective purchasing impacts drug shortages and discover strategies to enhance supply chain visibility and patient access to essential medications.

Dato-DXd is a promising first-line treatment for metastatic triple-negative breast cancer, enhancing patient outcomes.

Explore all 16 agreements struck thus far between pharmaceutical companies and the White House to adhere to most favored nation pricing for drugs sold in the United States.

KTX-1001, a novel oral inhibitor of NSD2, demonstrates early clinical activity and manageable safety in heavily pretreated multiple myeloma.

Pharmacists guide consumers in selecting quality dietary supplements, emphasizing the importance of USP verification for safety and efficacy.

Experts discuss groundbreaking data on pancreatic cancer treatment, revealing a 64% survival rate and its potential to transform patient care and outcomes.

Treatment with semaglutide offers benefits beyond solely cardiovascular risk reduction, lowering the risk of hospitalization across a range of comorbidities.

Pharmacists play a critical role in improving access to and affordability of GLP-1 therapies.

Innovative biodegradable nanoplatforms enhance cancer therapy by integrating targeted drug delivery and real-time imaging, revolutionizing oncology practices for pharmacists.

The FDA cited human factors unrelated to the drug's efficacy as the reason for rejection.